Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

76
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
76
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

199
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
199
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

92
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
92
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

66
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
66
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

78
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
78
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

83
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
83

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detecting T-cell clones of uncertain significance using anti-TRBC1-based flow cytometry.

Pathology·2026
Same author

CD39 mRNA therapy attenuates localized acute inflammation: A novel anti-inflammatory strategy using cationic nanoliposomes.

Molecular therapy. Nucleic acids·2026
Same author

Platelet-Targeted Self-Amplifying mRNA for Safe, Long-Acting Thromboprophylaxis.

Circulation research·2026
Same author

Prothrombotic genetic variants and cancer-associated venous thromboembolism: defining thrombotic risk across tumor types.

Haematologica·2026
Same author

Harnessing Immune Pathways for Stroke Recovery: Overcoming Challenges to Clinical Translation.

Circulation research·2026
Same author

Innovative γ-Oryzanol and KC2 Based Lipid Nanoparticles: OryKL Platform Provides Safe and Efficient In Vivo mRNA Delivery.

Small (Weinheim an der Bergstrasse, Germany)·2026

Related Experiment Video

Updated: Oct 25, 2025

A Porcine Model of Acute Autologous Pulmonary Embolism
07:44

A Porcine Model of Acute Autologous Pulmonary Embolism

Published on: September 6, 2024

593

Submassive Pulmonary Embolism: Current Perspectives and Future Directions.

Phillip C Nguyen1, Hannah Stevens1,2, Karlheinz Peter2,3,4,5

  • 1Department of Haematology, Alfred Hospital, Melbourne, VIC 3181, Australia.

Journal of Clinical Medicine
|August 7, 2021
PubMed
Summary

Submassive pulmonary embolism (PE) management remains challenging, with unclear benefits of systemic thrombolysis due to bleeding risks. This review clarifies current evidence and discusses emerging therapies for better patient outcomes.

Keywords:
pulmonary embolismsubmassive

More Related Videos

Establishment of a Minimally Invasive Rat Model of Pulmonary Embolism Using Autologous Blood Clots
08:02

Establishment of a Minimally Invasive Rat Model of Pulmonary Embolism Using Autologous Blood Clots

Published on: October 25, 2024

512
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.3K

Related Experiment Videos

Last Updated: Oct 25, 2025

A Porcine Model of Acute Autologous Pulmonary Embolism
07:44

A Porcine Model of Acute Autologous Pulmonary Embolism

Published on: September 6, 2024

593
Establishment of a Minimally Invasive Rat Model of Pulmonary Embolism Using Autologous Blood Clots
08:02

Establishment of a Minimally Invasive Rat Model of Pulmonary Embolism Using Autologous Blood Clots

Published on: October 25, 2024

512
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.3K

Area of Science:

  • Cardiology
  • Pulmonology
  • Vascular Medicine

Background:

  • Submassive pulmonary embolism (PE) presents intermediate risk, with outcomes worse than standard PE but less severe than high-risk PE.
  • Hemodynamically stable patients without cardiac dysfunction define standard-risk PE.
  • Systemic thrombolysis improves outcomes in high-risk PE but shows unclear benefits and increased bleeding in submassive PE.

Purpose of the Study:

  • To review and clarify current evidence on managing submassive PE.
  • To highlight limitations in existing definitions and prognostic factors for submassive PE.
  • To discuss novel and emerging therapies for submassive PE.

Main Methods:

  • Literature review of existing studies on submassive PE management.
  • Analysis of meta-analyses regarding thrombolytic therapy efficacy and safety.
  • Discussion of ongoing and preclinical research on novel treatments.

Main Results:

  • Systemic thrombolysis in submassive PE has not shown clear survival benefits, with risks of excess bleeding outweighing hemodynamic improvements.
  • Conflicting evidence exists regarding thrombolysis's ability to prevent long-term cardiorespiratory limitations (post-PE syndrome).
  • Current definitions and prognostic factors for submassive PE require refinement.

Conclusions:

  • Optimizing thrombolysis, potentially through catheter-based delivery or reduced dosing, is an area of active research.
  • Further investigation is needed to establish the role of thrombolytic therapy in preventing post-PE syndrome.
  • Novel therapies in development hold promise for improving outcomes in submassive PE patients.